The effect of multinational pharmaceutical companies on the developing world

Traditionally, the International Narcotics Control Board monitors the availability and distribution of illicit substances. However, this year they felt compelled to examine the global distribution, or lack of it, of licit drugs. At the same time, 39 pharmaceutical companies banded together to oppose a South African law that would allow the government to acquire and distribute essential drugs in the national interest. This feature examines the effects of the global pharmaceutical market on developing nations. The Australian Pharmaceutical Manufacturer's Association initially agreed to contribute to this feature, but then referred the matter to its members. We are awaiting contributions from GlaxoSmithKlein and Bristol Myers Squibb, both of which figure prominently in the debate and South African Challenge.

Back to 2001 Features
Back to Feature Archive main